Compare Royal Bank of Canada (RY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Bank of Canada vs TG Therapeutics Inc — how do they compare? Royal Bank of Canada trades at $210.37 (market cap $289.51B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Royal Bank of Canada is far larger — about 35× TG Therapeutics Inc's market cap, and Royal Bank of Canada pays a 2.42% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| RY | TGTX | |
|---|---|---|
Market Cap | $289.51B | $8.26B |
Sector | Financials | Health |
52-Week High | $217.87 | $59.06 |
52-Week Low | $128.46 | $26.39 |
Dividend Yield | 2.42% | — |
Enterprise Value | — | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Bank of Canada (RY) trades at $210.88, down 2.11% on the day, amid a bullish technical setup with support near $208 and resistance at $214. The company reported strong Q1 2026 earnings of $2.84 per share, beating estimates, and has a history of recent beats. Revenue grew to $66.53B in 2025, with a net income margin of 31.85% and a solid ROE of 17.17%. Analyst sentiment is mixed but leans positive, with a 43% buy rating.
RY's outlook is supported by consistent earnings performance and a robust dividend, recently increased to $1.76 per share. However, risks include elevated valuation multiples like a P/E of 19.42 and macroeconomic sensitivity. The stock offers stability through its banking diversification but faces headwinds from interest rate volatility and credit quality concerns.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
